hBD-1 vs REGN1033
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and REGN1033 (Trevogrumab (REGN1033)) — benefits, dosing, side effects, research data, and where to buy.
| Property | hBD-1 | REGN1033 |
|---|---|---|
| Category | Dental & Oral | Muscle & Performance |
| Full Name | Human beta-defensin 1 | Trevogrumab (REGN1033) |
| Molecular Weight | 4490 Da | ~150 kDa |
| Half-Life | minutes to hours | ~2-3 weeks |
| Amino Acids | 36 | N/A |
| Typical Dose | 1-10 µg/mL in experimental studies | 100-300 mg SC or equivalent trial dosing |
| Route | Topical/Intraoral | Subcutaneous / Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 60 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.